1 Broadway # 14, Cambridge, MA 02142
“We would expect at some point cancer would overtake vascular disease as a leading cause of death, both in the general population and among people with diabetes,” Song told Healio. “What surprises me most is the magnitude of the gap. If you look at the number for total cancer deaths, it is almost twice as […]
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.
SynDevRx, Inc., a clinical-stage biopharmaceutical company specializing in metabo-oncology, has announced the formation of its Prostate Cancer Medical Advisory Board (PCMAB), comprised of key opinion leaders and industry experts in clinical oncology research and prostate cancer patient care. The board’s overarching goal is to inform the development of SynDevRx’s lead drug candidate, SDX-7320, to target […]
With a global epidemic of obesity and diabetes and their known relationship to cancer, researchers and oncologists are turning their attention to metabolic hormones as promising new targets for cancer treatment.
Patients that are not cured with surgery or radiation are largely treated with endocrine therapies that target androgens or the androgen receptor (AR), a major driver of PCa. In response to androgen deprivation, most PCas progress to castrate resistant PCa. Epidemiological studies suggest that high-fat diets play important roles in PCa progression. Lipid metabolism rewires […]
Technology Networks recently spoke with Jim Shanahan, co-founder, chief business officer and director of SynDevRx, to explore the impact of metabolic dysfunction on treatment outcomes and learn more about the company’s lead compound SDX-7320.
Obesity has been linked to increased risk for over a dozen different types of cancer, as well as worse prognosis and survival. Over the years, scientists have identified obesity-related processes that drive tumor growth, such as metabolic changes and chronic inflammation, but a detailed understanding of the interplay between obesity and cancer has remained elusive. […]
Endogenous hyperinsulinemia has been proposed as one of the causal factors contributing to the association between obesity, diabetes, and increased cancer risk and mortality. Previous studies have examined the mechanisms through which hyperinsulinemia promotes cancer progression, but it is not understood how hyperinsulinemia contributes to cancer incidence. Disruption of cell polarity is an early event […]
SynDevRx, Inc., a clinical-stage oncology company, has submitted results of its Phase 1 dose escalation safety study in late-stage cancer patients with progressive, metastatic solid tumors to the United States Food and Drug Administration (FDA). The study’s primary endpoint was to establish the maximum tolerated dose and dosing schedule and the recommended Phase 2 dose […]
While diabetes/insulin-resistance and breast cancer are distinct diseases, insulin-signaling plays a central role in both illnesses. Insulin activates key cancer processes including EMT, tissue inflammation, motility, and angiogenesis. There are key opportunities to impact and prevent hyperinsulinemia during breast cancer prevention, surgical assessment, and chemotherapy. While it is not standard of care to test for […]